Open AccessRisk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy
Author(s) -
Stefan Mauss,
William M. Valenti,
Jean DePamphilis,
F. Le Duff,
Lisa Cupelli,
Sharon Passe,
Jonathan Solsky,
Francesca J. Torriani,
Douglas T. Dieterich,
Dominique Larrey
Publication year - 2004
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/00002030-200409030-00002
Subject(s) - decompensation , medicine , cirrhosis , ribavirin , gastroenterology , hepatitis c , hepatitis c virus , immunology , virus
Hepatic decompensation was reported from two recent trials (APRICOT and RIBAVIC) assessing interferon (IFN)-based treatment of hepatitis C virus (HCV) in HIV/HCV-coinfected patients. This paper identifies risk factors associated with hepatic decompensation in APRICOT.